Cardiac iron removal and functional cardiac improvement by different iron chelation regimens in thalassemia major...

Area of Science:

• Cardiology
• Hematology
• Medical Imaging

Background:

• Myocardial iron overload is a primary cause of heart failure and mortality in adult thalassemia major (TM) patients.
• Effective iron chelation therapy is crucial for managing cardiac complications in TM.

Purpose of the Study:

• To evaluate the efficacy of different iron chelation regimens in removing cardiac iron and improving cardiac function in TM patients.
• To assess changes in myocardial T2* values and left ventricular function using cardiac magnetic resonance (CMR).

Main Methods:

• Sixty-seven TM patients were divided into four groups based on chelation therapy: deferasirox, deferoxamine, combined deferoxamine/deferiprone, and deferiprone alone.
• T2* CMR was performed at baseline, 6-14 months, and 32 ± 7 months to assess myocardial iron levels.
• Left ventricular ejection fraction and volumes were analyzed to evaluate cardiac function.

Main Results:

• Progressive improvements in myocardial T2* were observed across different chelation groups.
• A significant improvement in left ventricular ejection fraction and reduction in ventricular volumes were noted in patients treated with deferasirox, particularly those with moderate baseline T2* values.
• Combination therapy demonstrated a rapid amelioration of cardiac T2* in patients with severe iron overload.

Conclusions:

• Rigorous compliance with iron chelation therapy, at appropriate doses, significantly improves myocardial T2* in TM patients.
• Deferasirox treatment is effective in improving left ventricular function.
• Combination therapy may offer faster improvement in cardiac T2* for severe siderosis.